Agonists at the nicotinic acetylcholine alpha 7 receptor (nAChR α7) subtype have the potential to treat cognitive deficits in patients with Alzheimer’s disease (AD) or schizophrenia. The gene discussed is CHRNA7; the disease is early-onset autosomal dominant Alzheimer disease.